The University of Wisconsin-Madison has had a T32 program for """"""""Physician Scientist Training in Cancer Medicine"""""""" since 1988. The purpose of this program has been to train physicians in laboratory-oriented research to prepare them for independent academic careers in cancer-focused medicine. This has been in response to a national problem of declining numbers of physician scientists entering research-related careers over the last three decades. The past success of our program can be judged by the numbers of our trainees who have continued in academic research-related careers. Over the 1993-2003 decade of funding, 19 of 26 (73%) trainees are in academic faculty positions. Since 2003, nearly all of our trainees continue in training for future academic careers. The current application requests support to continue this program, and describes our efforts to further improve on our past success with regards to training, monitoring outcomes, and our efforts to recruit trainees of diverse and underrepresented ethnic and cultural backgrounds.
Our specific aim i s to develop physicians as scientists with a strong foundation in basic and translational cancer research to help prepare them for careers in academic medicine.
There is a national shortage of physician scientists. This grant trains physicians in cancer research from specialties such as medical oncology, hematology, gastroenterology, pediatric oncology, and radiation oncology to developing laboratory/translational academic careers. Thus, this training is highly relevant to the mission of the National Cancer Institute.
|Shahzad, Mian M K; Felder, Mildred; Ludwig, Kai et al. (2018) Trans10,cis12 conjugated linoleic acid inhibits proliferation and migration of ovarian cancer cells by inducing ER stress, autophagy, and modulation of Src. PLoS One 13:e0189524|
|Rampurwala, Murtuza; Wisinski, Kari B; Burkard, Mark E et al. (2017) Phase 1b study of orteronel in postmenopausal women with hormone-receptor positive (HR+) metastatic breast cancer. Invest New Drugs 35:87-94|
|Wisinski, Kari B; Tevaarwerk, Amye J; Burkard, Mark E et al. (2016) Phase I Study of an AKT Inhibitor (MK-2206) Combined with Lapatinib in Adult Solid Tumors Followed by Dose Expansion in Advanced HER2+ Breast Cancer. Clin Cancer Res 22:2659-67|
|Hanson, Summer E; Kleinbeck, Kyle R; Cantu, David et al. (2016) Local delivery of allogeneic bone marrow and adipose tissue-derived mesenchymal stromal cells for cutaneous wound healing in a porcine model. J Tissue Eng Regen Med 10:E90-E100|
|Elsaid, M Y; Capitini, C M; Diamond, C A et al. (2016) Successful matched unrelated donor stem cell transplant in Hemoglobin Bart's disease. Bone Marrow Transplant 51:1522-1523|
|Hadac, Jamie N; Miller, Devon D; Grimes, Ian C et al. (2016) Heterochromatin Protein 1 Binding Protein 3 Expression as a Candidate Marker of Intrinsic 5-Fluorouracil Resistance. Anticancer Res 36:845-52|
|Graul-Conroy, Amanda; Hicks, Emily J; Fahl, William E (2016) Equivalent chemotherapy efficacy against leukemia in mice treated with topical vasoconstrictors to prevent cancer therapy side effects. Int J Cancer 138:3011-9|
|Rampurwala, Murtuza; Wisinski, Kari B; O'Regan, Ruth (2016) Role of the androgen receptor in triple-negative breast cancer. Clin Adv Hematol Oncol 14:186-93|
|Schneider, David F; Elfenbein, Dawn; Lloyd, Ricardo V et al. (2015) Lymph node metastases do not impact survival in follicular variant papillary thyroid cancer. Ann Surg Oncol 22:158-63|
|Blute Jr, Michael L; Rushmer, Timothy J; Shi, Fangfang et al. (2015) Renin-Angiotensin Inhibitors Decrease Recurrence after Transurethral Resection of Bladder Tumor in Patients with Nonmuscle Invasive Bladder Cancer. J Urol 194:1214-9|
Showing the most recent 10 out of 126 publications